Results 31 to 40 of about 7,855 (224)

Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons

BMC Neuroscience, 2008
Background Parkinson's disease (PD) is a neurological disorder characterized by the degeneration of nigrostriatal dopaminergic systems. Free radicals induced by oxidative stress are involved in the mechanisms of cell death in PD. This study clarifies the
Wang Feifei, Baba Tanefumi, Jing Meng, Morimoto Takamasa, Tajiri Naoki, Uozumi Takashi, Kameda Masahiro, Agari Takashi, Muraoka Kenichiro, Shingo Tetsuro, Yasuhara Takao, Ji Yuan Wen, Leung Hanbai, Matsui Toshihiro, Miyoshi Yasuyuki, Date Isao   +15 more
doaj   +1 more source

Edaravone for amyotrophic lateral sclerosis. [PDF]

Aust Prescr
europepmc   +3 more sources

July 2017 ENCALS statement on edaravone [PDF]

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017
Neurologists of the ENCALS centers throughout Europe have discussed the potential of edaravone as a new therapy for amyotrophic lateral sclerosis (ALS, Motor Neuron Disease, MND) at the ENCALS meeting, 18–20 May 2017, in Ljubljana, Slovenia.\ud \ud In May 2017, the US Food and Drug Administration (FDA) granted a license for the drug known as edaravone (
Al-Chalabi, A., Andersen, P.M., Chandran, S., Chio, A., Corcia, P., Couratier, P., Danielsson, O., de Carvalho, M., Desnuelle, C., Grehl, T., Grosskreutz, J., Holmøy, T., Ingre, C., Karlsborg, M., Kleveland, G., Christoph Koch, J., Koritnik, B., KuzmaKozakiewicz, M., Laaksovirta, H., Ludolph, A., McDermott, C., Meyer, T., Mitre Ropero, B., Mora Pardina, J., Nygren, I., Petri, S., Povedano Panades, M., Salachas, F., Shaw, P., Silani, V., Staaf, G., Svenstrup, K., Talbot, K., Tysnes, O.-B., Van Damme, P., van der Kooi, A., Weber, M., Weydt, P., Wolf, J., Hardiman, O., van den Berg, L.H.   +40 more
openaire   +15 more sources

Solid Lipid Nanoparticles Loaded with Edaravone for Inner Ear Protection After Noise Exposure

Chinese Medical Journal, 2015
Background: Antioxidants and the duration of treatment after noise exposure on hearing recovery are important. We investigated the protective effects of an antioxidant substance, edaravone, and its slow-release dosage form, edaravone solid lipid ...
Gang Gao, Ya Liu, Chang-Hua Zhou, Ping Jiang, Jian-Jun Sun   +4 more
doaj   +1 more source

Edaravone, a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone [PDF]

Redox Report, 2016
3-Methyl-1-phenyl-2-pyrazolin-5-one (edaravone) is used in clinical treatment of acute brain infarction to rescue the penumbra, based on its ability to prevent lipid peroxidation by scavenging lipid peroxyl radicals. Here, we show that edaravone also reacts with peroxynitrite to yield 4-NO-edaravone as the major product and 4-NO2-edaravone as a minor ...
Akio, Fujisawa, Yorihiro, Yamamoto
openaire   +2 more sources

Microglial HVCN1 Deficiency Improves Movement and Survival of SOD1G93A ALS Mice by Enhancing Microglial Migration and Neuroprotection

Advanced Science, EarlyView.
Hydrogen voltage gated channel 1 (HVCN1) is upregulated in microglia of both ALS patients and its mouse model. HVCN1 deficiency enhances microglial migration via suppressing Akt signaling, promotes neurotrophic capacity and motor function, and prolongs survival of the SOD1G93A ALS mice. This study identifies HVCN1 as a novel, promising druggable target
Fan Wang, Ke‐Yu Zhang, Lang‐Jian Zhu, Wei‐Jue Li, Yang Wu, Xiang Gao, Xiao‐Ru Ma, Xiu‐Hua Yin, Jian‐Bin Wu, Xiao‐Kang Ye, Zhao‐Jun Dong, Di‐Xian Wang, Zhe Zhou, Shao‐Dong Wang, Lei Han, Zhi‐Nong Jiang, Jing‐Wei Zhao   +16 more
wiley   +1 more source

Edaravone prevents high glucose-induced injury in retinal Müller cells through thioredoxin1 and the PGC-1α/NRF1/TFAM pathway

Pharmaceutical Biology, 2021
Context Oxidative injury in a high-glucose (HG) environment may be a mechanism of diabetic retinopathy (DR) and edaravone can protect retinal ganglion cells by scavenging ROS. Objective To explore the effect of edaravone on HG-induced injury.
Juanping Yin, Xinke Chen
doaj   +1 more source

Establishment of Ischemia-Reperfusion Model in Cynomolgus Macaques and Effects of Edaravone Intervention

Shiyan dongwu yu bijiao yixue, 2023
ObjectiveTo establish an ischemia-reperfusion model in cynomolgus macaques and to analyse the effects of edaravone intervention.MethodsA total of fifteen adult male cynomolgus macaques were randomly divided into three groups: sham operation (Sham group ...
PAN Mengxian, HUANG Xiaojiao, HUANG Zhongli, SHEN Guo, ZHANG Pengfei, ZENG Yong, LI Wenfeng, ZHOU Huabo, WEI Zhumei   +8 more
doaj   +1 more source

Edaravone Derivatives Containing NO-Donor Functions

Journal of Medicinal Chemistry, 2008
A new series of polyvalent drugs obtained by joining edaravone with NO-donor moieties is described. All compounds display high antioxidant power together with NO-dependent vasodilator properties. The analysis of a number of molecular descriptors shows that the antioxidant activity, which is tightly linked to the presence of the edaravone substructure ...
CHEGAEV, Konstantin, CENA, Clara, GIORGIS, Marta, ROLANDO, Barbara, TOSCO, Paolo, BERTINARIA, Massimo, FRUTTERO, Roberta, Pier Alain Carrupt, GASCO, Alberto   +8 more
openaire   +4 more sources

Neuroprotective Nanoplatform Integrating Antioxidant MXene Nanozymes and Ferroptosis Inhibitors for Targeted Therapy of Cerebral Ischemia‐Reperfusion Injury

Advanced Science, EarlyView.
Cerebral ischemia‐reperfusion injury (CIRI) is a key pathological process limiting the efficacy of stroke therapy. This study has developed an innovative, multifunctional, brain‐targeted nanoplatform (RFP) containing MXene nanoenzymes and ferroptosis inhibitors.
Lu Wang, Chao Hou, Shuo Li, Lizhi Yang, Yiqun Lin, Sen Wang, Xiaohua Jia, Hui Hui, Wen He, Wei Zhang   +9 more
wiley   +1 more source